Pfizer Q2 2026 earnings beat, revenue guidance raised

On an adjusted basis, net reached 77 cents per share, clearing the 68-cent statement estimate, according to CNBC. On a reported basis, Pfizer posted a nonaccomplishment per stock of $0.04, reflecting $4.3 cardinal successful non-cash intangible plus impairments.

The guidance update incorporates astir $1.5 cardinal successful upside from non-COVID products, though that summation was tempered by a simplification successful the company's forecast for COVID-19 treatments, which Pfizer present pegs astatine astir $4 cardinal for the year, compared with a anterior anticipation of astir $5 billion. The institution near its full-year adjusted net outlook unchanged astatine $2.80 to $3.00 per share.

Revenue maturation was led by respective products. Eliquis roseate 19% operationally, driven by higher nett prices successful the U.S. and stronger planetary demand. Padcev climbed 23% operationally connected accrued marketplace stock successful bladder cancer. Lorbrena grew 37% operationally, portion the Vyndaqel household roseate 8%. Paxlovid fell 95% operationally amid little COVID-19 corruption rates, and Comirnaty declined 34% operationally. Excluding Comirnaty and Paxlovid, revenues grew 5% operationally.

Pfizer besides announced an enlargement of its cost-savings programs. The institution said it expects an further $2.5 cardinal successful nett outgo savings from 2027 done 2029, comprising $1 cardinal from its ongoing outgo realignment programme and $1.5 cardinal from the adjacent signifier of its manufacturing optimization program.

Pfizer Chairman and CEO Albert Bourla said successful a connection that the company's obesity programme is advancing "with meaningful momentum" and that its oncology portfolio "remains a root of strength."

Pfizer is navigating a enactment modulation successful its concern department: CFO Dave Denton is departing the institution connected Aug. 15, with Cecile Guegan acceptable to measurement successful arsenic interim CFO the pursuing day. Guegan, who is presently elder vice president of concern for Pfizer's planetary biopharmaceutical business, joined the institution successful 2005 and played a relation successful integrating Seagen into Pfizer successful 2024. Pfizer is conducting an interior and outer hunt for a imperishable replacement.

Pfizer shares were up 1.8%, to $25.50, successful premarket trading.